Anti-Inflammatory Effects of 6-Methylcoumarin in LPS-Stimulated RAW 264.7 Macrophages via Regulation of MAPK and NF-κB Signaling Pathways

Persistent inflammatory reactions promote mucosal damage and cause dysfunction, such as pain, swelling, seizures, and fever. Therefore, in this study, in order to explore the anti-inflammatory effect of 6-methylcoumarin (6-MC) and suggest its availability, macrophages were stimulated with lipopolysaccharide (LPS) to conduct an in vitro experiment. The effects of 6-MC on the production and levels of pro-inflammatory cytokines (interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha) and inflammatory mediators (nitric oxide (NO), prostaglandin E-2 (PGE(2))) in LPS-stimulated RAW 264.7 cells were examined. The results showed that 6-MC reduced the levels of NO and PGE(2) without being cytotoxic. In addition, it was demonstrated that the increase in the expression of pro-inflammatory cytokines caused by LPS stimulation, was decreased in a concentration-dependent manner with 6-MC treatment. Moreover, Western blot results showed that the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), which increased with LPS treatment, were decreased by 6-MC treatment. Mechanistic studies revealed that 6-MC reduced the phosphorylation of the mitogen-activated protein kinase (MAPK) family and I kappa B alpha in the MAPK and nuclear factor-kappa B (NF-kappa B) pathways, respectively. These results suggest that 6-MC is a potential therapeutic agent for inflammatory diseases that inhibits inflammation via the MAPK and NF-kappa B pathways.

Automated summary

The study demonstrated that 6-MC reduced the levels of nitric oxide and prostaglandin E-2 without causing cytotoxicity, and also decreased the expression of pro-inflammatory cytokines in a concentration-dependent manner in LPS-stimulated cells. Western blot results showed that 6-MC treatment decreased the protein levels of iNOS and COX-2 induced by LPS, while mechanistic studies revealed its inhibitory effects on the MAPK and NF-kappa B pathways.